BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

BCRX 10.61 -0.45 (-4.07%)
price chart
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ...  Wall Street Pit
Business NC sold; FDA fast-tracks BioCryst drug; Uber caps storm prices ...  WRAL Tech Wire
Company Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the application for ...
BioCryst Pharmaceuticals Given Average Recommendation of "Buy" by ...  The Legacy
BioCryst Pharmaceuticals, Inc. Price Target Update  Bar and Graph Report
Brokerage Firm Price Target on BioCryst Pharmaceuticals, Inc.
Equity Analysts at the Brokerage Firm, JP Morgan, maintains their rating on the shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). JP Morgan has a Overweight rating on the counter. As per the latest research report, the brokerage house lowers the ...
Stocks Underperform for the Week: BioCryst Pharmaceuticals Inc , Seventy ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has lost 2.31% during the past week and dropped 8.46% in the past 4 weeks.
Stock in Focus: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's development programs at ...
BioCryst Pharmaceuticals Raised to "Outperform" at Zacks (NASDAQ:BCRX)  Mideast Time
Shares Outperform Index: Ship Finance International Ltd , BioCryst ...  Rock Hill Daily
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule pharmaceuticals that block key enzymes involved in the pathogenesis of diseases.
Traders Buzz: Arch Coal Inc. (NYSE:ACI), BioCryst Pharmaceuticals (NASDAQ ...  Property Mentor
Related articles »  
Why BioCryst Pharmaceuticals Inc. Shares Soared
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Crushes It on Rare Immune Disorder Drug Trial  24/7 Wall St.
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ...  MarketWatch
Related articles »  
CFO of BioCryst Pharmaceuticals, Inc. Sells Company Shares
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Staab Thomas R Ii, Senior Vice President and CFO of Biocryst Pharmaceuticals Inc, unloaded 9,500 shares at an average price of $12.56 on December 29, 2014. The total amount of the transaction was worth ...
BioCryst Pharmaceuticals, Inc. Analyst Rating Update
Research firm Zacks has rated BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and has ranked it at 1, indicating that its shares are a Outperform.
Buzz Stocks: Tesla Motors, Inc., Chipotle Mexican Grill, Inc., and BioCryst ...  Schaeffers Research (blog)
Pre-market Bullish Movers: Himax Technologies (ADR) (NASDAQ:HIMX ...  Property Mentor
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ...  Seeking Alpha (registration)
BioCryst Pharmaceuticals (BCRX) Continues to Rise on Potential Ebola Treatment  Equities.com
Related articles »